A novel approach to target inflammatory diseases
SCIENTIFIC ADVISORY BOARD
Chairperson: Sébastien Gibot, M.D., PhD.
Professor Sébastien GIBOT is co-founder of INOTREM. Prof. Sébastien Gibot is Professor of Intensive Care Medicine at Hopital Central, Nancy, France. He managed Dr Marc Derive’s thesis and thus co-developed anti-sepsis compounds. Prof. Sébastien Gibot has over 15 years’ experience of fundamental and clinical research in the field of immunotherapy of sepsis. He authored 67 peer reviewed papers and has 4 patents in the field. Prof. Sébastien Gibot is known and recognized as the international specialist of TREM-1 and he is largely implicated in the scientific and development activities of INOTREM Company.
Jacky Vonderscher, PhD.
Founder of Vonderscher&Co GmbH
Senior executive with a broad R&D experience in the pharmaceutical industry
Most recently Senior VP Head of Translation Research Sciences at Roche in USA and Switzerland (2010-2012)
Senior VP head of Molecular Medicine Labs at Roche (2008-2010)
Previously held other senior positions with Novartis in the USA and Switzerland (1979 to 2008)
Known for his leading role in the discovery and development of Sandimmum Neoral® in the 90s
Co-inventor on the first patents of Mycophenolic Acid Sodium salt (Myfortic® Product) and of Everolimus (Certican® and Afinitor® Products)
Board member of Inatherys and ObsEva and SAB member of Inotrem
Jacques Mizrahi, PhD.
Jacques Mizrahi Ph.D, has been a senior executive with 20 plus years of big pharma global leadership experience in Discovery and Development (GSK, E. Lilly, Roche). Jacques has led several successful drug development programs in vascular, cardiovascular and metabolic diseases. At Roche, as Global Therapy Area Head, he led the discovery and development of several new molecular entities for Acute Coronary Syndromes, Diabetes and Diabetes complications and has developed significant expertise in bridging the discovery of new target pathways and the clinics via translational medicine projects. Jacques obtained his Ph.D in Pharmacology from the University of Sherbrooke, Canada and then held postdoctoral fellowships at each of Sherbrooke Medical School and at INSERM Paris where he focused on protein biochemistry. Jacques has over 100 peer reviewed publications. Additionally, he contributes to peer journal Editorial Boards and sits on Advisory Boards of academic, biotech and venture capital organizations.
Denis Hochstrasser, M.D., PhD.
Pr Denis Hochstrasser is Vice-Rector/ Vice President of Geneva University, in charge of the research and computer sciences sectors. He is also chairman of the Genetic & Laboratory Medicine Department of the Geneva University Hospital. He is as a Board certified physician in internal medicine & in clinical chemistry. At the academic level, he is full Professor both to Geneva’s Department of Human Protein Sciences, Medicine Faculty and to the School of Pharmacy, Sciences Faculty. He was one of the founders of the Swiss Institute for Bioinformatics, of the Swiss Centre for Applied Human Toxicology and also of Biobank Swiss Foundation. He is a scientific founder of Geneva Proteomics Inc, Geneva Bioinformatics SA and of Eclosion SA. He is a board member of the CTI certification board for the Swiss Government and of Viollier laboratories. His research focus on the discovery of clinical biomarkers in brain, pancreas and kidney diseases, in human toxicology and the development of proteomic & clinical chemistry related technologies such as clinical mass spectrometry.
Pierre Launay, PhD.
Co-founder and CSO Inatherys. Doctor in Immunology, Inserm research director and team “Avenir” director of the U699 unit. Doctoral student at Necker hospital, Pierre has more than 17 years of experience in basic research on monoclonal antibodies and their therapeutic implications and has published some of his work in scientific journals such as Cell, Nature et Science. He coordinated several projects on inflammation (NIH Grant R01, ANR-Genopath) and cancer (ARC) as well as a research program in allergology (Foundation for medical research). Former Instructor at Harvard Medical School in Boston for 6 years, he characterized new therapeutic targets (ion channels) in inflammation. He was also a scientific consultant for 4 years for Synta Pharmaceuticals biotechnology company located in Lexington. As such, he took part in the creation, in 2001, of a research department within the company on ion channels’ agonists for applications in inflammation. He undertook the Challenge+ training program of French management and business school (HEC).
Albert Heck, PhD.
The research group of Albert Heck at Utrecht University has a large track record in quantitative proteomics and the analysis of protein post-translational modifications. For example, he introduced TiO2 as enrichment material for the targeted analysis of phosphopeptides, introduced the use of a protease named LysN that in conjunction with ETD provides unique sequence ladders that are straightforward to interpret and has an extensive track record in developing quantitative proteomics strategies, introducing metabolic stable isotope labeling in multicellular organisms and stable isotope labeling by using chemical approaches. The Heck group is also leading in macromolecular or native mass spectrometry, which enables the analysis of intact proteins and protein assemblies by mass spectrometry. The group develops mass spectrometers dedicated for this work and applies these technologies to study the structure and dynamics of for instance transcription complexes, such as RNA polymerase, and virus assembly. The infrastructure and technology available at the Heck group includes state-of-the art proteomics equipment, with over 20 mass spectrometers and expert proteomics technology to study a variety of post-translational modifications, quantitate changes in protein interaction networks and the detailed characterization of intact protein complexes.
CLINICAL DEVELOPMENT ADVISORY BOARD
Chairperson: Sebastien Gibot, M.D., PhD.
Professor Sebastien GIBOT is co-founder of INOTREM. Pr Sebastien Gibot is Professor of Intensive Care Medicine at Hopital Central, Nancy, France. He managed Dr Marc Derive’s thesis and thus co-developed anti-sepsis compounds. Pr Sebastien Gibot has over 15 years’ experience of fundamental and clinical research in the field of immunotherapy of sepsis. He authored 67 peer reviewed papers and has 4 patents in the field. Pr Sebastien Gibot is known and recognized as the international specialist of TREM-1 and he is largely implicated in the scientific and development activities of INOTREM Company.
Pierre-François Laterre, M.D.
Pierre-François Laterre, MD, is professor of medicine and the Head of the medical-surgical intensive care unit at Saint Luc University Hospital at the Université Catholique de Louvain, Brussels, Belgium. In 1990 he graduated in Internal Medicine and in 1991 in Intensive Care Medicine at Saint Luc University Hospital, Université Catholique de Louvain, Brussels: University Hospital Practionner at CHRU of Nancy (France) and Research Fellow at the Johns Hopkins Hospital (Baltimore, USA) in 93. He has dedicated most of his professional and scientific activity to the diagnosis, investigation and treatment of sepsis and especially its interaction with the coagulation cascade, inflammation and host response. Liver Failure and Transplantation, ARDS, Acute Renal Failure, Infectious Diseases are his topics of interest. He has a large experience in multicenter, randomized, double blind studies and he is Director of the Clinical Coordinating Center of the Compass trial (PAF inhibition in sepsis), CAPTIVATE, ACCESS, ART 123 trials. He is member of the European Society of Intensive Care Medicine, Society of CCM and of several advisory boards. He is currently president of the French Society of Critical Care.
Tom Van Der Poll, M.D.
Tom van der Poll is Professor of Medicine in the Academic Medical Center (AMC), University of Amsterdam, the Netherlands. He is Head of the Center of Experimental and Molecular Medicine and Chair of the Division of Infectious Diseases in this institution. Van der Poll is board certified in Internal Medicine and Infectious Diseases. His training included a postdoctoral research fellowship in Cornell University Medical College in New York (1993-1995). Van der Poll is a former Fellow of the Royal Dutch Academy of Arts and Sciences (1995-2000). Van der Poll is council member of the Global Sepsis Alliance (GSA, www.globalsepsisalliance.org) and immediate past Chair of the International Sepsis Forum (ISF, www.internationalsepsisforum.org), an organization headed by a council of international experts and opinion leaders that focuses on improving the management of sepsis and septic shock. He is a member of the “International Task Force Committee for Sepsis Definitions” (installed by ESICM & SCCM) and the “Surviving Sepsis Guidelines Committee”. Van der Poll’s research focuses on the innate immune and procoagulant response during sepsis.
Bruno François, M.D.
Dr. François is specialist in Intensive Care medicine and Anaesthesiology at the University Hospital of Limoges, France. He works in a 22 bed medical/surgical ICU and is the head of the Limoges Clinical Investigation Center (Inserm CIC-P 1435) of which main expertise is Infectious Diseases in critically ill patients. He has been national coordinator for numerous emergency trials especially in Sepsis, VAP and VAP prevention, and has participated in several advisory boards for Sepsis and VAP multinational trials, independent Clinical Evaluation Committees and Adjudication Committees. He is author of many publications in Infectious Disease in the ICU especially about Sepsis and VAP and is also reviewer for several medical journals in the ICU field. He has an expertise in the practical bedside organization of clinical research in the ICU. He has also an interest in more translational studies and research about the immunological disorders of Sepsis evaluated by flow cytometry and its potential treatments. He created the CRICS network dedicated to clinical research in Sepsis trials in 2007 and is now co-leading the French TRIGGERSEP research network (F-CRIN certification within ECRIN) which integrate all research activities in Sepsis from basic science to clinical trials. Since 2012, he is coordinating the COMBACTE consortium within the IMI framework.
Philippe Jacqmin, PhD.
Philippe Jacqmin is a Director and one of the founders of Exprimo. He was born in 1956 in Belgium and obtained his Pharm.D. degree from the University of Louvain in 1979 and his Ph.D. degree in Pharmaceutical Sciences from the same University in 1984. From 1984 to 1988 he was successively assistant and first assistant at the Department of Pharmacology at the University of Louvain and was responsible for the Therapeutic Drug Monitoring Unit at the St. Luc University Clinics. From 1988 to 1993 Philippe worked as Group Leader Pharmacokinetics and Drug Metabolism at the Searle European Development Centre in Belgium. From 1993 to 2000 he held several positions within the Departments of Non-clinical and Clinical Pharmacokinetics at the Janssen Research Foundation (a Johnson & Johnson company) in Belgium where he was one the initiators of the Exploratory Development group. From 2000 to 2002, he worked for Pharsight Corporation as Consultant within the European Scientific Affairs Group. Philippe has 15 years of preclinical as well as clinical drug development experience. He is author or co-author of more than 35 original research papers and approximately 60 scientific abstracts and contributed to six textbooks dealing with pharmacokinetics and PK/PD modelling. He also contributed to several registration dossiers for new drug applications. Philippe lives in Belgium.
François Vandenhende, PhD.
Dr. Francois Vandenhende is the founder and CEO of ClinBAY, a statistical CRO that delivers cost-effective quantitative solutions to pharmaceutical decision makers. Dr. Vandenhende is a clinical statistician, specialized in Bayesian methods and adaptive designs. He provides statistical insight into scientific advisory boards for various biotech companies. He is also managing strategic alliances for ClinBAY with several global pharmaceutical customers. Prior to joining ClinBAY, Francois started his career at Merck for 1 year, then moved to Eli Lilly and Company for 14 years, where he ended as the global head of CNS early phase statistics. He has a Ph.D. degree in statistics from UCL, Belgium.